CANDEL THERAPEUTICS INC

Candel Therapeutics’ CEO Executes Planned 23,447-Share Sale Amid Bullish Outlook, No Signs of Pessimism

Insider selling at Candel Therapeutics signals disciplined, plan‑based trading, not pessimism, as leadership remains invested in its oncolytic platform.

CANDEL THERAPEUTICS INC
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

01/07/2026, 22:40

3 minutes to read

Candel Therapeutics’ Board Goes All‑In: Eight Directors Grab 32,000 Zero‑Priced Options as Share Price Surges and Social Media Buzz Explodes

Insider buys 32k Candel Therapeutics options for zero‑price, signaling board confidence in upcoming clinical milestones and potential rally.

CANDEL THERAPEUTICS INC
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

24/06/2026, 22:52

3 minutes to read